These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
6. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Herazo-Maya JD; Sun J; Molyneaux PL; Li Q; Villalba JA; Tzouvelekis A; Lynn H; Juan-Guardela BM; Risquez C; Osorio JC; Yan X; Michel G; Aurelien N; Lindell KO; Klesen MJ; Moffatt MF; Cookson WO; Zhang Y; Garcia JGN; Noth I; Prasse A; Bar-Joseph Z; Gibson KF; Zhao H; Herzog EL; Rosas IO; Maher TM; Kaminski N Lancet Respir Med; 2017 Nov; 5(11):857-868. PubMed ID: 28942086 [TBL] [Abstract][Full Text] [Related]
7. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Tzouvelekis A; Herazo-Maya JD; Slade M; Chu JH; Deiuliis G; Ryu C; Li Q; Sakamoto K; Ibarra G; Pan H; Gulati M; Antin-Ozerkis D; Herzog EL; Kaminski N Respirology; 2017 Apr; 22(3):486-493. PubMed ID: 27761978 [TBL] [Abstract][Full Text] [Related]
8. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Scott MKD; Quinn K; Li Q; Carroll R; Warsinske H; Vallania F; Chen S; Carns MA; Aren K; Sun J; Koloms K; Lee J; Baral J; Kropski J; Zhao H; Herzog E; Martinez FJ; Moore BB; Hinchcliff M; Denny J; Kaminski N; Herazo-Maya JD; Shah NH; Khatri P Lancet Respir Med; 2019 Jun; 7(6):497-508. PubMed ID: 30935881 [TBL] [Abstract][Full Text] [Related]
9. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Clynick B; Corte TJ; Jo HE; Stewart I; Glaspole IN; Grainge C; Maher TM; Navaratnam V; Hubbard R; Hopkins PMA; Reynolds PN; Chapman S; Zappala C; Keir GJ; Cooper WA; Mahar AM; Ellis S; Goh NS; De Jong E; Cha L; Tan DBA; Leigh L; Oldmeadow C; Walters EH; Jenkins RG; Moodley Y Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34675050 [TBL] [Abstract][Full Text] [Related]
10. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Durheim MT; Collard HR; Roberts RS; Brown KK; Flaherty KR; King TE; Palmer SM; Raghu G; Snyder LD; Anstrom KJ; Martinez FJ; Lancet Respir Med; 2015 May; 3(5):388-96. PubMed ID: 25890798 [TBL] [Abstract][Full Text] [Related]
11. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Feng H; Zhao Y; Li Z; Kang J Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705 [TBL] [Abstract][Full Text] [Related]
12. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H; Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760 [TBL] [Abstract][Full Text] [Related]
13. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Jessen H; Hoyer N; Prior TS; Frederiksen P; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB Respir Res; 2021 Jul; 22(1):205. PubMed ID: 34261485 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050 [TBL] [Abstract][Full Text] [Related]
15. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. Khan F; Stewart I; Howard L; McKeever TM; Jones S; Hearson G; Braybrooke R; Edwards C; Jenkins G; Saini G BMJ Open Respir Res; 2019; 6(1):e000439. PubMed ID: 31258922 [TBL] [Abstract][Full Text] [Related]
16. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Stuart BD; Lee JS; Kozlitina J; Noth I; Devine MS; Glazer CS; Torres F; Kaza V; Girod CE; Jones KD; Elicker BM; Ma SF; Vij R; Collard HR; Wolters PJ; Garcia CK Lancet Respir Med; 2014 Jul; 2(7):557-65. PubMed ID: 24948432 [TBL] [Abstract][Full Text] [Related]
17. Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts. Maddali MV; Moore AR; Sinha P; Newton CA; Kim JS; Adegunsoye A; Ma SF; Strek ME; Chen CH; Linderholm AL; Zemans RL; Moore BB; Wolters PJ; Martinez FJ; Rogers AJ; Raj R; Noth I; Oldham JM Am J Respir Crit Care Med; 2024 Aug; 210(4):455-464. PubMed ID: 38913573 [No Abstract] [Full Text] [Related]
18. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260 [TBL] [Abstract][Full Text] [Related]
19. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409 [TBL] [Abstract][Full Text] [Related]
20. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis. Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]